AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20482894 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hand BMD loss (>‐0.003 g/cm2) in the first year of RA
Number of subjects: 256
Study 20482894 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand BMD loss in the first year
Number of subjects: 256
Study 20482894 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive joint damage in the first year
Number of subjects: 256
Study 20482894 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-citrullinated protein antibody positivity
Number of subjects: 256
Study 17966028 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 52
Study 17966028 — intervention group
Group type: COMPARATOR
Intervention: Cast treatment
Number of subjects: 52
Study 16210834 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) of 0.625 mg plus medroxyprogesterone acetate (MPA) of 2.5 mg (n = 79)
Number of subjects: 286
Study 16210834 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) of 0.625 mg plus medroxyprogesterone acetate (MPA) of 5 mg (n = 77)
Number of subjects: 286
Study 16210834 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone of 2.5 mg (n = 76)
Number of subjects: 286
Study 16210834 — intervention group
Group type: COMPARATOR
Intervention: Calcium (Ca) of 1,000 mg (n = 54)
Number of subjects: 286
Study 12270249 — intervention group
Group type: EXPERIMENTAL
Intervention: Monodose inhaler (Miat)
Number of subjects: 12
Study 12270249 — intervention group
Group type: COMPARATOR
Intervention: Pulmicort Turbuhaler DPI
Number of subjects: 12
Study 10323625 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (1 mg/kg body weight)
Number of subjects: 50
Study 10323625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8691896 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective rearfoot orthotic device
Number of subjects: 25
Study 8691896 — intervention group
Group type: COMPARATOR
Intervention: Standard shoe with no device
Number of subjects: 25
Study 1908584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin (10 mg PO)
Number of subjects: 30
Study 1908584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1908584 — intervention group
Group type: COMPARATOR
Intervention: No pill
Number of subjects: 30
Study 6409135 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural anaesthesia with 0.5% bupivacaine with adrenaline continued into the postoperative period (24 h)
Number of subjects: 30
Study 6409135 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia with controlled ventilation, using nitrous oxide in oxygen and fentanyl i.v.
Number of subjects: 30
Study 29862491 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% colchicine cream
Number of subjects: 36
Study 29862491 — intervention group
Group type: COMPARATOR
Intervention: Methyl aminolaevulinate photodynamic therapy (MAL-PDT)
Number of subjects: 36
Study 27228268 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 75
Study 27228268 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Acupoint Stimulation (TEAS)
Number of subjects: 75
Study 27228268 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 75
Study 24569032 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 2216
Study 24569032 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 2216
Study 22546733 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled, forced-air warming gown
Number of subjects: 30
Study 22546733 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital gown and prewarmed standard cotton blanket
Number of subjects: 30
Study 21203389 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard SP‐IPTp
Number of subjects: 3333
Study 21203389 — intervention group
Group type: EXPERIMENTAL
Intervention: IST and treatment with SP
Number of subjects: 3333
Study 21203389 — intervention group
Group type: EXPERIMENTAL
Intervention: IST and treatment with AQ+AS
Number of subjects: 3333
Study 21203389 — intervention group
Group type: COMPARATOR
Intervention: SP‐IPTp
Number of subjects: 3333
Study 16895615 — intervention group
Group type: COMPARATOR
Intervention: Air and oxygen mixture through a Hudson style face mask (FiO2 of 0.21‐0.25)
Number of subjects: 60
Study 16895615 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO2 of 0.40‐0.60 through an identical Hudson style face mask
Number of subjects: 60
Study 16307045 — intervention group
Group type: EXPERIMENTAL
Intervention: Enerlit‐Clima (bioactive succinate‐based food additive)
Number of subjects: 0
Study 16307045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11948271 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir
Number of subjects: 160
Study 11948271 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valganciclovir
Number of subjects: 160
Study 11948271 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir and Oral valganciclovir
Number of subjects: 160
Study 10451813 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 51
Study 10451813 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17 beta‐estradiol
Number of subjects: 51
Study 10451813 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta‐estradiol
Number of subjects: 51
Study 10451813 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 8519718 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position with 3 mL lidocaine 1.5% and 12 mL bupivacaine 0.75%
Number of subjects: 40
Study 8519718 — intervention group
Group type: COMPARATOR
Intervention: Supine position with 3 mL lidocaine 1.5% and 12 mL bupivacaine 0.75%
Number of subjects: 40
Study 8519718 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 40
Study 8519718 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 40
Study 2130290 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg phenobarbital
Number of subjects: 8
Study 2130290 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg phenobarbital
Number of subjects: 8
Study 2130290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 475546 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly experienced psychotherapists
Number of subjects: 15
Study 475546 — intervention group
Group type: COMPARATOR
Intervention: College professors
Number of subjects: 15
Study 475546 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated groups
Number of subjects: 15
Study 31647838 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Sleep Unit (VSU)
Number of subjects: 186
Study 31647838 — intervention group
Group type: COMPARATOR
Intervention: Hospital Routine (HR)
Number of subjects: 186
Study 28669962 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 µg/kg + 0.25% ropivacaine (0.20 mL/kg)
Number of subjects: 80
Study 28669962 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.50 µg/kg + 0.25% ropivacaine (0.20 mL/kg)
Number of subjects: 80
Study 28669962 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.75 µg/kg + 0.25% ropivacaine (0.20 mL/kg)
Number of subjects: 80
Study 28669962 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.25% ropivacaine only)
Number of subjects: 80
Study 28669962 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study 25772196 — intervention group
Group type: EXPERIMENTAL
Intervention: Omelette
Number of subjects: 30
Study 25772196 — intervention group
Group type: COMPARATOR
Intervention: Cottage Cheese
Number of subjects: 30
Study 24159085 — intervention group
Group type: EXPERIMENTAL
Intervention: Gompertz function analysis
Number of subjects: 469
Study 21205129 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy occurred
Number of subjects: 532
Study 21205129 — intervention group
Group type: COMPARATOR
Intervention: No pregnancy occurred
Number of subjects: 532
Study 19470629 — intervention group
Group type: EXPERIMENTAL
Intervention: IDet (2 mU/kg . min for 4 h, followed by 4 mU/kg . min for 1 h)
Number of subjects: 10
Study 19470629 — intervention group
Group type: COMPARATOR
Intervention: HI (1 mU/kg . min for 4 h, followed by 2 mU/kg . min for 1 h)
Number of subjects: 10
Study 19470629 — intervention group
Group type: EXPERIMENTAL
Intervention: IDet
Number of subjects: 10
Study 19470629 — intervention group
Group type: COMPARATOR
Intervention: HI
Number of subjects: 10
Study 17719702 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol-enriched products (20 g low-fat margarine and 250 ml low-fat milk delivering 2.3g plant sterols/d)
Number of subjects: 46
Study 17719702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 15601557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral H101 injection combined with PF regimen (cisplatin + 5-fluorouracil)
Number of subjects: 160
Study 15601557 — intervention group
Group type: COMPARATOR
Intervention: PF regimen alone
Number of subjects: 160
Study 15601557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral H101 injection combined with AF regimen (adriamycin + 5-fluorouracil)
Number of subjects: 160
Study 15601557 — intervention group
Group type: COMPARATOR
Intervention: AF regimen alone
Number of subjects: 160
Study 11523980 — intervention group
Group type: EXPERIMENTAL
Intervention: stannous fluoride dentifrice and hyG Brnde ionizing brush without a battery
Number of subjects: 32
Study 11523980 — intervention group
Group type: COMPARATOR
Intervention: stannous fluoride dentifrice and hyG Brnde ionizing brush with a battery
Number of subjects: 32
Study 9551737 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg at 30 L x min[‐1]
Number of subjects: 18
Study 9551737 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg at 90 L x min[‐1]
Number of subjects: 18
Study 9551737 — intervention group
Group type: COMPARATOR
Intervention: Placebo at 30 L x min[‐1]
Number of subjects: 18
Study 9551737 — intervention group
Group type: COMPARATOR
Intervention: Placebo at 90 L x min[‐1]
Number of subjects: 18
Study 8823352 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 2390155 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lignocaine with higher pH
Number of subjects: 20
Study 2390155 — intervention group
Group type: COMPARATOR
Intervention: 1% lignocaine with standard pH
Number of subjects: 20
Study 7020917 — intervention group
Group type: EXPERIMENTAL
Intervention: L-phenylalanine mustard (L-PAM)
Number of subjects: 158
Study 7020917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, 5-fluorouracil, and methotrexate (CMF)
Number of subjects: 158
Study 7020917 — intervention group
Group type: COMPARATOR
Intervention: R.T. plus L-PAM
Number of subjects: 158
Study 7020917 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 158
Study 7020917 — intervention group
Group type: COMPARATOR
Intervention: R.T. plus CMF
Number of subjects: 158
Study 30234669 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training (Group SIM) with 60 minutes of simulation practice
Number of subjects: 0
Study 30234669 — intervention group
Group type: COMPARATOR
Intervention: No simulation training (Group CON)
Number of subjects: 0
Study 28730328 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine patch (5, 10, 15, and 20 μg/h)
Number of subjects: 0
Study 28730328 — intervention group
Group type: COMPARATOR
Intervention: Oral tramadol (150, 200, 250, and 300 mg)
Number of subjects: 0
Study 28730328 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Buprenorphine and Tramadol)
Number of subjects: 0
Study 26492082 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid mixture deficient in dopamine precursors (APTD)
Number of subjects: 12
Study 26492082 — intervention group
Group type: COMPARATOR
Intervention: Nutritionally-balanced amino acid mixture (BAL)
Number of subjects: 12
Study 26492082 — intervention group
Group type: EXPERIMENTAL
Intervention: APTD
Number of subjects: 12
Study 26492082 — intervention group
Group type: COMPARATOR
Intervention: BAL
Number of subjects: 12
Study 24196866 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 130
Study 24196866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 23089349 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflated pneumatic tourniquet (group A, n = 40)
Number of subjects: 80
Study 23089349 — intervention group
Group type: COMPARATOR
Intervention: Deflated pneumatic tourniquet (group B, n = 40)
Number of subjects: 80
Study 19777852 — intervention group
Group type: EXPERIMENTAL
Intervention: Chaihu Shihuang soup once a day for 7 days
Number of subjects: 60
Study 19777852 — intervention group
Group type: COMPARATOR
Intervention: Dachaihu soup once daily for 7 days
Number of subjects: 60
Study 18085153 — intervention group
Group type: EXPERIMENTAL
Intervention: Acup-moxibustion plus western medicine
Number of subjects: 132
Study 18085153 — intervention group
Group type: COMPARATOR
Intervention: Western medication
Number of subjects: 132
Study 15382818 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of a 2nd language
Number of subjects: 197
Study 15382818 — intervention group
Group type: EXPERIMENTAL
Intervention: Deceptive interaction condition
Number of subjects: 197
Study 15382818 — intervention group
Group type: COMPARATOR
Intervention: Deceptive-context condition
Number of subjects: 197
Study 15382818 — intervention group
Group type: COMPARATOR
Intervention: Older peer condition
Number of subjects: 197
Study 11528347 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 19
Study 11528347 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 19
Study 9370106 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous GLP-1 (administered i.v. or s.c.)
Number of subjects: 37
Study 9370106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 1396820 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg t.i.d.
Number of subjects: 157
Study 1396820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 4011640 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.66 ml/kg of body weight
Number of subjects: 24
Study 4011640 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 ml/l of total body water
Number of subjects: 24
Study 31325345 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% watery solution of glycerol
Number of subjects: 0
Study 31325345 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenated glycerol triester (Aequasyal)
Number of subjects: 0
Study 31325345 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed product (Salient)
Number of subjects: 0
Study 29691286 — intervention group
Group type: COMPARATOR
Intervention: Sedentary lifestyle (compared to physically active)
Number of subjects: 10626
Study 29691286 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age and dementia
Number of subjects: 10626
Study 29691286 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression and alcohol consumption
Number of subjects: 10626
Study 29691286 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor physical function, physical inactivity, and smoking
Number of subjects: 10626
Study 29691286 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-specific models
Number of subjects: 10626
Study 26778329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab or Bevacizumab treatment for CME
Number of subjects: 1131
Study 25439038 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathy
Number of subjects: 162
Study 25439038 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo (control)
Number of subjects: 162
Study 22380577 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates (weekly alendronate/risedronate)
Number of subjects: 198
Study 22380577 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient counselling
Number of subjects: 198
Study 20215101 — intervention group
Group type: EXPERIMENTAL
Intervention: Search by story topic (yes)
Number of subjects: 353
Study 20215101 — intervention group
Group type: EXPERIMENTAL
Intervention: Search by writer profile (yes)
Number of subjects: 353
Study 20215101 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of search by story topic and writer profile
Number of subjects: 353
Study 20215101 — intervention group
Group type: COMPARATOR
Intervention: No search by story topic (no)
Number of subjects: 353
Study 20215101 — intervention group
Group type: COMPARATOR
Intervention: No search by writer profile (no)
Number of subjects: 353
Study 17921395 — intervention group
Group type: EXPERIMENTAL
Intervention: Custards containing 20 g cooked acetylated high‐amylose maize starch (HAMSA)
Number of subjects: 0
Study 17921395 — intervention group
Group type: EXPERIMENTAL
Intervention: Custards containing 20 g cooked propionylated high‐amylose maize starch (HAMSP)
Number of subjects: 0
Study 17921395 — intervention group
Group type: EXPERIMENTAL
Intervention: Custards containing 20 g cooked butyrylated high‐amylose maize starch (HAMSB)
Number of subjects: 0
Study 17921395 — intervention group
Group type: EXPERIMENTAL
Intervention: Custards containing unacylated high‐amylose maize starch (Hylon VII, HAMS)
Number of subjects: 0
Study 17921395 — intervention group
Group type: COMPARATOR
Intervention: Custards containing low‐amylose maize starch (3401C, LAMS)
Number of subjects: 0
Study 16160589 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg doxazosin/d
Number of subjects: 30
Study 16160589 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg doxazosin/d
Number of subjects: 30
Study 16160589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11865965 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/day synthetic conjugated estrogens (n = 35)
Number of subjects: 50
Study 11865965 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 50
Study 10075186 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment videotape
Number of subjects: 87
Study 10075186 — intervention group
Group type: COMPARATOR
Intervention: Control videotape
Number of subjects: 87
Study 7728980 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of 300 g of cooked Brussels sprouts per day for 1 week
Number of subjects: 10
Study 7728980 — intervention group
Group type: COMPARATOR
Intervention: Glucosinolate-free diet (control period)
Number of subjects: 10
Study 1922194 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorolfine 50 mg
Number of subjects: 118
Study 1922194 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorolfine 100 mg
Number of subjects: 118
Study 1922194 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole 500 mg
Number of subjects: 118
Study 6348177 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg acyclovir intravenously three times daily
Number of subjects: 37
Study 6348177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 6348177 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 37
Study 30839416 — intervention group
Group type: EXPERIMENTAL
Intervention: Omidenepag isopropyl 0.002%
Number of subjects: 0
Study 30839416 — intervention group
Group type: EXPERIMENTAL
Intervention: Omidenepag isopropyl 0.0025%
Number of subjects: 0
Study 30839416 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 0
Study 30839416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30197644 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-human T-lymphocyte globulin (ATLG) perfusion (n = 24 kidneys)
Number of subjects: 50
Study 30197644 — intervention group
Group type: COMPARATOR
Intervention: Saline perfusion (Control group, n = 26 kidneys)
Number of subjects: 50
Study 26791555 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (40% energy from protein) / 3.6 carbohydrate:fat preload
Number of subjects: 36
Study 26791555 — intervention group
Group type: COMPARATOR
Intervention: Low-protein (9% energy from protein) / 0.4 carbohydrate:fat preload
Number of subjects: 36
Study 26791555 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (40% energy from protein) / 0.4 carbohydrate:fat preload
Number of subjects: 36
Study 26791555 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate preloads
Number of subjects: 36
Study 26791555 — intervention group
Group type: EXPERIMENTAL
Intervention: All preloads
Number of subjects: 36
Study 24861583 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g acetazolamide
Number of subjects: 12
Study 24861583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 22348447 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary biventricular pacing
Number of subjects: 0
Study 22348447 — intervention group
Group type: COMPARATOR
Intervention: Standard pacing (atrial inhibited pacing or atrial-synchronous right ventricular pacing)
Number of subjects: 0
Study 22348447 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 0
Study 20652304 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PPC/POBH
Number of subjects: 30
Study 20652304 — intervention group
Group type: COMPARATOR
Intervention: PPC and in‐the‐bag IOL implantation
Number of subjects: 30
Study 18204148 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg/day, n=30)
Number of subjects: 71
Study 18204148 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypolipemic diet (n=28)
Number of subjects: 71
Study 18204148 — intervention group
Group type: COMPARATOR
Intervention: Untreated control (n=13)
Number of subjects: 71
Study 16354891 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (triphasic ethinyl estradiol 35 microg + norethindrone 0.5 to 1 mg for 12 cycles of 28 days)
Number of subjects: 183
Study 16354891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 16354891 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 183
Study 12575340 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract extraction combined with IOL implantation through no-sitch small incision
Number of subjects: 93